In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
|Articles|February 10, 2022
Daily OTC Pearl: Sagely Naturals Pain Relief Cream
Author(s)Saro Arakelians, PharmD
Sagely Naturals Pain Relief Cream combines CBD with powerful botanicals, peppermint, and menthol.
Advertisement
OTC/Lifestyle Pearl of the Day: Sagely Naturals Pain Relief Cream
Indication: Sagely Naturals offers restorative, nourishing and moisturizing treatment for the skin.
Insight:
- Sagely Relief & Recovery CBD Cream contains a blend of plant-based ingredients along with CBD.
- Essential oils of menthol and peppermint are soothing and cooling.
- Ingredients: Water (aqua), caprylic/capric triglyceride, cetyl alcohol, cetearyl alcohol, glycerin, menthol, capryloyl glycerin/sebacic acid copolymer, cetearyl glucoside, stearic acid, xanthan gum, marula (sclerocarya birrea) seed oil, diheptyl succinate, cannabis sativa extract (hemp CBD), cannabis sativa seed oil (hemp), tocopherol, argan (argania spinosa) kernel oil, safflower (carthamus tinctorius) seed oil, peppermint (mentha piperita) oil, caprylhydroxamic acid, and glyceryl caprylate.
- Caution: For external use only.
- Avoid contact with eyes.
- Keep out of reach of children and if pregnant or nursing, ask a health care professional before use.
- Discontinue use if irritation or discomfort occurs.
Sources:
Advertisement
Related to this article
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
5